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Pseudoalteromonas haloplanktis 
TAC125 produces 4-hydroxybenzoic 
acid that induces pyroptosis in 
human A459 lung adenocarcinoma 
cells
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Tedesco4, Renato Fani5, Gennaro Marino  1,6, Donatella de Pascale4, Adrianna Ianora2, 
Ermenegilda Parrilli1, Thomas Ostenfeld Larsen3, Giovanna Romano2 & Maria Luisa Tutino  1
In order to exploit the rich reservoir of marine cold-adapted bacteria as a source of bioactive 
metabolites, ethyl acetate crude extracts of thirteen polar marine bacteria were tested for their 
antiproliferative activity on A549 lung epithelial cancer cells. The crude extract from Pseudoalteromonas 
haloplanktis TAC125 was the most active in inhibiting cell proliferation. Extensive bioassay-guided 
purification and mass spectrometric characterization allowed the identification of 4-hydroxybenzoic 
acid (4-HBA) as the molecule responsible for this bioactivity. We further demonstrate that 4-HBA 
inhibits A549 cancer cell proliferation with an IC50 value ≤ 1 μg ml−1, and that the effect is specific, since 
the other two HBA isomers (i.e. 2-HBA and 3-HBA) were unable to inhibit cell proliferation. The effect 
of 4-HBA is also selective since treatment of normal lung epithelial cells (WI-38) with 4-HBA did not 
affect cell viability. Finally, we show that 4-HBA is able to activate, at the gene and protein levels, a 
specific cell death signaling pathway named pyroptosis. Accordingly, the treatment of A549 cells with 
4-HBA induces the transcription of (amongst others) caspase-1, IL1β, and IL18 encoding genes. Studies 
needed for the elucidation of mode of action of 4-HBA will be instrumental in depicting novel details of 
pyroptosis.
Lung cancer is an extremely important health concern that affects millions of people worldwide1,2, and any pro-
gress leading to improvement of cancer survival rates is a global priority. Patients with lung cancer generally have 
a poor prognosis with a 5-year survival2. Traditional cancer chemotherapy has mainly been based on the use of 
highly cytotoxic drugs that non-specifically target all dividing cells and may therefore only result in a modest 
improvement in patients that become immunosuppressed as chemotherapeutics kill all proliferating cells includ-
ing monocytes and lymphocytes. For this reason, a new trend in anticancer research has arisen focusing on the 
discovery of new natural drugs that induce specific programmed cell death mediated by immunogenic signals. A 
recently discovered form of immunogenic cell death is represented by pyroptosis. This pathway differs from that 
of apoptosis as it is uniquely mediated by caspase-1 (CASP1) activation, which in turn triggers the formation of 
an “inflammasome”, a cytosolic complex with inflammatory features3 linked to interleukin 1β (IL1β) release for 
immune cell recruitment.
1Department of Chemical Sciences, University of Naples “Federico II”, Complesso Universitario Monte S. Angelo, 
Via Cintia, Naples, 80126, Italy. 2Integrative Marine Ecology Department, Stazione Zoologica Anton Dohrn, Villa 
Comunale, Naples, 80121, Italy. 3Department of Biotechnology and Biomedicine, Søltofts Plads, Building 221, 
Technical University of Denmark, DK-2800 Kgs., Lyngby, Denmark. 4Institute of Protein Biochemistry, CNR, Via 
Pietro Castellino 111, Naples, 80131, Italy. 5Department of Biology, LEMM, Laboratory of Microbial and Molecular 
Evolution Florence, University of Florence, I-50019, Sesto Fiorentino (FI), Italy. 6University Suor Orsola Benincasa, Via 
Santa Caterina da Siena, 32, Naples, 80132, Italy. Filomena Sannino and Clementina Sansone contributed equally to 
this work. Correspondence and requests for materials should be addressed to G.R. (email: romano@szn.it) or M.L.T. 
(email: tutino@unina.it)
Received: 2 August 2017
Accepted: 18 December 2017
Published: xx xx xxxx
OPEN
www.nature.com/scientificreports/
2SCIENtIFIC RepoRTs |  (2018) 8:1190  | DOI:10.1038/s41598-018-19536-2
Many of the anticancer drugs used in clinical practice today are natural products or derivatives thereof4 and 
the continued and systematic exploration of natural sources, such as marine microbiota, is expected to lead to 
the discovery of different and unforeseen compounds with interesting biological activities, including antican-
cer activity5. Marine bacteria have proven to be a unique and promising source of biologically active natural 
products6. The production of anticancer drugs by microorganisms can be advantageous in comparison to other 
natural sources, such as plants, due to i) the possibility of genetically engineering microbes and ii) their higher 
production rates7.
Amongst marine bacteria, cold-adapted microorganisms represent an untapped reservoir of biodiversity 
endowed with an interesting chemical repertoire. It has been already shown that cold-adapted bacteria produce 
valuable bioactive secondary metabolites, such as anti-biofilm molecules8–10, antimicrobials11,12 and compounds 
displaying various other pharmaceutically-relevant activities13. In this context, polar marine bacteria could likely 
be a potential source of new molecules with antiproliferative activity.
In the present study we screened ethyl acetate extracts of thirteen different cultivable cold-adapted bacteria on 
A549 cells, a lung adenocarcinoma cell line, which represents a suitable model for the study of Non Small Cancer 
Lung Cells having typical characteristics in terms of proliferation index and malignancy14. We demonstrate that 
Pseudoalteromonas haloplanktis TAC12515,16 (P. haloplanktis TAC125) is able to produce an antiproliferative 
agent. In particular, this bacterium produces 4-hydroxybenzoic acid that specifically activates pyroptosis in A549 
cells without affecting viability in normal cells.
Results
Screening for antiproliferative activity of polar bacteria ethyl acetate extracts, and production 
conditions optimization. Ethyl acetate crude extracts of thirteen bacterial strains (Table S1) were tested 
for their antiproliferative activity using the MTT assay on lung adenocarcinoma A54914 cells. The ethyl acetate 
extract of uninoculated GG medium was used as a negative control. A549 tumor cells were treated with different 
concentrations (1, 10 and 100 μg ml−1) of the total extracts for 24 hours (data not shown) and 48 hours, and com-
pared with cells treated with the negative control extract. The highest concentration tested (100 μg ml−1) induced 
a decrease in the percentage of viable cells for most of the extracts (Figure S1). Interestingly, the crude extract 
of P. haloplanktis TAC125 inhibited cell viability in a dose dependent manner, with a calculated half Inhibition 
Concentration (IC50) of about 30 μg ml−1. Based on these results, we focused on P. haloplanktis TAC125 as a 
potential source of antiproliferative compounds.
To test whether the composition of growth medium affected the production of antiproliferative compound(s), 
the Antarctic bacterium was grown in different media: a rich medium (TYP)17; a synthetic medium (GG)16; and 
a medium containing alternatively L-glutamate or D-gluconate as source of carbon and nitrogen. Extract of P. 
haloplanktis TAC125 grown in GG medium displayed the highest antiproliferative activity on A549 cells (data 
not shown).
To increase production of antiproliferative compound(s), P. haloplanktis TAC125 was grown in GG medium in 
an automatic bioreactor. The cell extract of P. haloplanktis TAC125 grown in the bioreactor displayed an IC50 value 
of about 1 μg ml−1, indicating a clear enhancement in production yields under this growth condition (Figure S2).
Bioactivity guided purification and identification of the antiproliferative compound from 
Pseudoalteromonas haloplanktis TAC125. Pre-fractionation of the P. haloplanktis TAC125 extract was 
achieved on a reversed phase column, and fractions were tested by the MTT assay on A549 lung cancer cells 
(Fig. 1, panel A). Fractions 1 and 4 were shown to inhibit A549 cells in a dose dependent manner and both 
fractions displayed IC50 values of about 10 μg ml−1. Fraction 4 was discarded as it was also shown to exert a high 
cytotoxicity towards the non transformed lung epithelial WI-38 cells (Fig. 1, panel B).
The bioactive fraction 1 was subjected to a further purification step and the resulting fractions were tested 
for antiproliferative activity with the MTT assay on A549 cells (Fig. 1, panel C). Fraction 1E was identified as the 
most active with an IC50 value of about 0,8 μg ml−1 and very interestingly this fraction displayed no toxic effect 
towards the WI-38 normal cell line (Fig. 1, panel B).
The active fraction 1E was analysed by Ultra-high performance liquid chromatography-diode array 
detection-high-resolution mass spectrometry (UHPLC-DAD-HRMS) with tandem MS/HRMS fragmentation 
that revealed a single compound which was tentatively identified as 4-hydroxybenzoic acid (4-HBA) from a 
search in a comprehensive in-house standard collection of microbial metabolites18.
The identification of 4-HBA was verified by comparison of retention time, monoisotopic mass for the pseu-
domolecular ion [M-H]−, MS/HRMS spectra (10 eV, 20 eV and 40 eV) from negative electrospray ionization (ESI) 
mode and UV spectrum with a commercially available standard (Fig. 2).
A comparable cytotoxic effect was displayed for the isolated pure compound (1E) and the commercial stand-
ard of 4-HBA when tested in the same experiment using the MTT assay on A549 cells (Figure S3). To investigate 
the structural features essential for this antiproliferative activity, the effect of the hydroxybenzoic acid structural 
isomers (2-, 3-, and 4-HBA) were analyzed. The results of the MTT assay on A549 cells indicated that 4-HBA was 
the most active isomer, with an IC50 ≤ 1 μg ml−1 (Figure S4).
Mechanism of action for 4-hydroxybenzoic acid. The specific molecular pathway activated by 4-HBA 
was defined through a PCR array experiment aimed to evaluate changes in expression of the main genes involved 
in the most common signaling pathways of cell death19 (Table 1). A549 cells were treated with 1 µg ml−1 of 4-HBA 
(IC50 concentration) and after 2 hours of incubation, cells were recovered and subjected to a real time qPCR 
analysis. Only two-fold difference in expression values with respect to the control (untreated cells) were used to 
identify up- and/or down-regulated genes, respectively (Table 1). We found that the expression of the following 
key genes involved in pyroptotic cell death signalling20 were all up-regulated including the Caspase Recruitment 
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Domain-Containing Protein 5 (PYCARD), Bcl2 Modifying Factor (BMF), Caspase-1 (CASP1), Interleukin-1β 
(IL1β) and Interleukin-18 (IL18) (Fig. 3, panel A, Table 1).
Regarding other death cell signaling pathways19, the observed up-regulation of the gene encoding X-linked 
inhibitor of apoptosis (XIAP) indicated that the 4-HBA treatment inhibited the canonical apoptotic pathway 
in A549 cells. Furthermore, microarray results highlighted that genes involved in the extrinsic apoptotic path-
way were strongly down-regulated: CD40 ligand (CD40L), Fas ligand (FasL), Myelin associated glycoprotein 
(MCL1) and Tumor necrosis factor receptor superfamily, member 11b (TNFRS11B). As for the expression of 
key genes involved in the necrotic pathway, they were also down-regulated: Forkhead box I1 (FOXL1), Olfactory 
receptor, family 10, subfamily J, member 3 (OR10J3), S100 calcium binding protein A7A (S100A7A) and 
Junctophilin 3 (JPH3). Finally, homeostatic and detoxification cell pathways such as autophagy were also strongly 
Figure 1. Panel (A): Cell viability of lung adenocarcinoma cells (A549) treated for 48 hours with three different 
concentrations (1, 10 and 100 µg ml−1) of 9 fractions of Pseudoalteromonas haloplanktis TAC125 obtained on 
a C18 column by a Isolera One purification system. Panel (B): Cell viability of lung normal fibroblast cells (WI-
38) treated for 48 hours with three different concentrations (1, 10 and 100 µg ml−1) of three samples: Fraction 4 
and Fraction 1 from fractionation on a C18 column by Isolera One system; 1E from following purification step 
by HPLC of the Fraction 1. Panel (C): Cell viability of lung adenocarcinoma cells (A549) treated for 48 hours 
with three different concentrations (1, 10 and 100 µg ml−1) of 7 fractions (from 1A to 1G) of Pseudoalteromonas 
haloplanktis TAC125 obtained from Fraction 1 on a semipreparative HPLC. In all the above experiments, red 
bar represents untreated cells (control). Three independent assays were performed in triplicate; viability data are 
shown as mean ± S.D.
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down-regulated: Interferon gamma (IFNG), Estrogen receptor 1 (ESR1), Huntingtin (HTT), Insulin-like growth 
factor 1 (IGF1), Insulin (INS), Immunity-related GTPase family M (IRGM), Kv channel interacting protein 1 
(KCNIP1), RAB25 member RAS oncogene family and Synaptonemal complex protein 2 (SYCP2). The genes 
involved in other death cell signaling pathways were not differently expressed in A549 cells treated with 4-HBA 
(Table 1).
Since caspase-1 plays a crucial role in the pyroptotic cell signaling pathway, its protein levels in A549 treated 
cells were analyzed by immunoblot (Figure S5). 4-HBA treatment was carried out under the same conditions used 
for PCR array analysis (1 µg ml−1), but the cells were collected after 24 hours, since changes in protein levels were 
more evident at this time point. In Fig. 3, the increase in pro-caspase-1 levels (panel B) and appearance of the P20 
caspase-1 protein cleavage fragment (panel C) can be seen only in treated samples, thus confirming that A549 cell 
death induced by 4-HBA treatment was due to caspase-1 activation.
Discussion
Marine organisms represent an attractive source of marine natural products in view of the high hit rates of marine 
molecules as antitumor and antibiotic drug leads21. Especially, polar marine bacteria are an unexploited hoard 
of biodiversity equipped with an interesting chemical repertoire13. In this study, we evaluated the antiprolifer-
ative activity on tumor cells of ethyl acetate crude extracts of cold-adapted bacteria belonging to the genera 
Pseudoalteromonas, Pseudomonas, Psychrobacter and Psychromonas. Even though nine out of the thirteen ana-
lysed strains belong to the same genus (Pseudoalteromonas), their recent genome-wide comparison attested a 
quite remarkable diversity, with a large proportion of unique genes22. This analysis prompted us to use all thirteen 
strains in the initial screening. The P. haloplanktis TAC125 crude extract was shown to be the most active in 
inhibiting cell proliferation. The bioactivity guided purification scheme highlighted the presence of more than 
one fraction endowed with anti-proliferative activity when tested on A549 cells. The fraction that was non toxic 
on WI-38 cells was subjected to a further fractionation step. 4-Hydroxybenzoic acid (4-HBA) was identified as 
the single compound responsible for the observed antiproliferative activity. 4-HBA is a primary metabolite as it 
is one of the products of chorismate lyase, which converts chorismic acid into pyruvate and 4-HBA. The latter 
molecule is then addressed towards the ubiquinone biosynthetic pathway. It is interesting to note that another 
Pseudoalteromonas strain, Pseudoalteromonas flavipulchra, was reported to produce 4-HBA, to which an antimi-
crobic activity was assigned23. In this paper, we demonstrate that 4-HBA inhibits A549 cancer cell proliferation 
with an IC50 value ≤1 μg ml−1. Although we have not currently identified the cellular target(s) of 4-HBA, we 
show that its effect is specific, since the other HBA isomers (i.e. 2-HBA and 3-HBA) were unable to induce any 
Figure 2. ESI − extracted ion chromatograms, UV spectra and MS/HRMS spectra at 40 eV for the single active 
compound (1E) and commercial standard of 4-hydroxybenzoic acid (4-HBA).
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Unigene Refseq Symbol Description
Fold 
Regulation
St. 
deviation
Genes up-regulated by 4-HBA treatment
Hs.249227 NM_130463 PYCARD Caspase Recruitment Domain-Containing Protein 5 9.1022 0.009952
Hs.591104 NM_033503 BMF Bcl2 modifying factor 8.2385 0.009952
Hs.2490 NM_033292 CASP1 Caspase 1, apoptosis-related cysteine peptidase (interleukin 1, beta, convertase) 13.0597 1.382987
Hs.743398 NM_213607 IL1B Interleukin-1 beta 15.6858 5.424528
Hs.472860 NM_001250 IL18 Interleukin-18 3.523 3.141189
Hs.32949 NM_005218 DEFB1 Defensin, beta 1 16.3404 4.718064
Hs.656958 NM_002647 PIK3C3 Phosphoinositide-3-kinase, class 3 2.0217 0.291856
Hs.356076 NM_001167 XIAP X-linked inhibitor of apoptosis 2.0656 0.551179
Genes down-regulated by 4-HBA treatment
Hs.592244 NM_000074 CD40LG CD40 ligand −12.6362 0.009952
Hs.744830 NM_000125 ESR1 Estrogen receptor 1 −3.7381 0.545221
Hs.2007 NM_000639 FASLG Fas ligand (TNF superfamily, member 6) −13.6362 0.009952
Hs.87236 NM_012188 FOXI1 Forkhead box I1 −13.2454 0.09952
Hs.518450 NM_002111 HTT Huntingtin −2.13 0.109509
Hs.856 NM_000619 IFNG Interferon, gamma −45.0004 2.581419
Hs.160562 NM_000618 IGF1 Insulin-like growth factor 1 (somatomedin C) −3.8688 1.644252
Hs.700350 NM_000207 INS Insulin −6.5181 1.580485
Hs.519680 NM_001145805 IRGM Immunity-related GTPase family, M −12.6362 0.009952
Hs.592068 NM_020655 JPH3 Junctophilin 3 −4.7242 0.148375
Hs.484111 NM_014592 KCNIP1 Kv channel interacting protein 1 −14.7747 0.309055
Hs.643440 NM_002361 MAG Myelin associated glycoprotein −147.3426 5.001374
Hs.553833 NM_001004467 OR10J3 Olfactory receptor, family 10, subfamily J, member 3 −15.6362 0.009952
Hs.632469 NM_020387 RAB25 RAB25, member RAS oncogene family −10.6362 0.009952
Hs.442337 NM_176823 S100A7A S100 calcium binding protein A7A −170.5556 5.299868
Hs.202676 NM_014258 SYCP2 Synaptonemal complex protein 2 −8.3494 4.692137
Hs.81791 NM_002546 TNFRSF11B Tumor necrosis factor receptor superfamily, member 11b −16.8362 0.009952
Genes not regulated by 4-HBA treatment
Hs.431048 NM_005157 ABL1 C-abl oncogene 1, non-receptor tyrosine kinase −1.1138 0.066919
Hs.525622 NM_005163 AKT1 V-akt murine thymoma viral oncogene homolog 1 −1.2832 0.033352
Hs.552567 NM_001160 APAF1 Apoptotic peptidase activating factor 1 −1.0289 0.640226
Hs.434980 NM_000484 APP Amyloid beta (A4) precursor protein 1.1123 0.181838
Hs.264482 NM_004707 ATG12 ATG12 autophagy related 12 homolog (S. cerevisiae) −1.0132 0.215062
Hs.529322 NM_017974 ATG16L1 ATG16 autophagy related 16-like 1 (S. cerevisiae) 1.0268 0.6199
Hs.477126 NM_022488 ATG3 ATG3 autophagy related 3 homolog (S. cerevisiae) 1.0191 0.225597
Hs.486063 NM_004849 ATG5 ATG5 autophagy related 5 homolog (S. cerevisiae) −1.0137 0.143056
Hs.740389 NM_006395 ATG7 ATG7 autophagy related 7 homolog (S. cerevisiae) 1.0824 0.863897
Hs.624291 NM_004324 BAX BCL2-associated X protein 1.0065 0.26068
Hs.150749 NM_000633 BCL2 B-cell CLL/lymphoma 2 1.533 0.00217
Hs.227817 NM_004049 BCL2A1 BCL2-related protein A1 −1.1823 0.709671
Hs.516966 NM_138578 BCL2L1 BCL2-like 1 −1.3254 0.177263
Hs.469658 NM_006538 BCL2L11 BCL2-like 11 (apoptosis facilitator) 3.3266 0.907015
Hs.716464 NM_003766 BECN1 Beclin 1, autophagy related −1.1248 0.158217
Hs.696238 NM_001166 BIRC2 Baculoviral IAP repeat containing 2 1.2091 0.152718
Hs.127799 NM_001165 BIRC3 Baculoviral IAP repeat containing 3 −1.0495 0.272117
Hs.235095 NM_017891 C1orf159 Chromosome 1 open reading frame 159 1.6566 2.489837
Hs.368982 NM_032982 CASP2 Caspase 2, apoptosis-related cysteine peptidase −1.5993 0.099699
Hs.141125 NM_004346 CASP3 Caspase 3, apoptosis-related cysteine peptidase −1.1233 0.054198
Hs.654616 NM_032992 CASP6 Caspase 6, apoptosis-related cysteine peptidase 1.2447 0.035162
Hs.9216 NM_001227 CASP7 Caspase 7, apoptosis-related cysteine peptidase −1.0595 0.663683
Hs.329502 NM_001229 CASP9 Caspase 9, apoptosis-related cysteine peptidase −1.3565 0.389132
Hs.390736 NM_003879 CFLAR CASP8 and FADD-like apoptosis regulator 1.1123 0.206097
Hs.351327 NM_017828 COMMD4 COMM domain containing 4 −1.2485 0.210456
Hs.520898 NM_001908 CTSB Cathepsin B −1.0859 0.166632
Continued
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anti-proliferative effect on the cancer cell line tested. Furthermore, the effect of 4-HBA is selective, as the treat-
ment of normal lung epithelium cell line (WI-38) with 4-HBA does not affect cell viability.
We demonstrate that at gene and protein levels, 4-HBA is able to activate pyroptosis in A549 cells. Pyroptotic 
cell death was reported as a caspase-1-dependent cell death of macrophages when infected by Salmonella typh-
imurium24,25. In contrast to apoptosis, pyroptosis is a pro-inflammatory type of cell death due to the activation 
of caspase-1 leading to the formation of the inflammasome, resulting in the release of the pro-inflammatory 
cytokines IL-1β and IL-183. Our results show that treatment of A549 cancer cells with 4-HBA induces the tran-
scription of (amongst others) caspase-1, IL1β, and IL18 encoding genes. Furthermore, a clear accumulation of 
caspase-1 and its activated form (pro-caspase-1) was observed at the protein level. Interestingly, the only death 
signaling pathway activated was pyroptosis, as demonstrated by the down-regulation of key genes involved in 
apoptosis, necrosis and autophagy. This clearly indicates that 4-HBA is specifically recognized by tumor cells that 
fall into the inflammasome cascade. At the morphological level, 4-HBA treated cells showed a typical membrane 
swelling ascribable to cell lysis occurring during pyroptosis. The observation that the viability of WI-38 was not 
affected by treatment with 4-HBA suggests that this microbial derived metabolite cannot be considered a bacterial 
virulence factor. On the other hand, its selective anti-proliferative activity against cancer cells (at least the tested 
in the present study) indicates a molecular target mainly present in transformed cells. To test if 4-HBA was also 
able to inhibit the proliferation of other transformed cell lines, colon rectal adenocarcinoma (HT29) cell line was 
Unigene Refseq Symbol Description
Fold 
Regulation
St. 
deviation
Hs.181301 NM_004079 CTSS Cathepsin S −1.5347 0.507273
Hs.578973 NM_015247 CYLD Cylindromatosis (turban tumor syndrome) −1.157 0.156944
Hs.654567 NM_005848 DENND4A DENN/MADD domain containing 4A −1.0189 0.299697
Hs.484782 NM_004401 DFFA DNA fragmentation factor, 45 kDa, alpha polypeptide −1.1597 0.394894
Hs.100058 NM_006426 DPYSL4 Dihydropyrimidinase-like 4 −1.5649 1.078326
Hs.158688 NM_015904 EIF5B Eukaryotic translation initiation factor 5B −1.4494 0.055674
Hs.667309 NM_000043 FAS Fas (TNF receptor superfamily, member 6) 1.137 0.229523
Hs.1437 NM_000152 GAA Glucosidase, alpha; acid 1.0603 0.628058
Hs.80409 NM_001924 GADD45A Growth arrest and DNA-damage-inducible, alpha 1.1215 0.028813
Hs.269027 NM_014568 GALNT5 UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 5 (GalNAc-T5) 1.8231 0.096225
Hs.444356 NM_002086 GRB2 Growth factor receptor-bound protein 2 1.3273 0.242009
Hs.29169 NM_024610 HSPBAP1 HSPB (heat shock 27 kDa) associated protein 1 1.3892 1.706257
Hs.643120 NM_000875 IGF1R Insulin-like growth factor 1 receptor −1.1904 0.05958
Hs.632273 NM_181509 MAP1LC3A Microtubule-associated protein 1 light chain 3 alpha −1.0059 0.049965
Hs.138211 NM_002750 MAPK8 Mitogen-activated protein kinase 8 1.0652 0.595847
Hs.632486 NM_021960 MCL1 Myeloid cell leukemia sequence 1 (BCL2-related) 1.1497 0.049134
Hs.618430 NM_003998 NFKB1 Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 −1.0531 0.547016
Hs.513667 NM_003946 NOL3 Nucleolar protein 3 (apoptosis repressor with CARD domain) −1.7116 0.206745
Hs.177766 NM_001618 PARP1 Poly (ADP-ribose) polymerase 1 −1.0047 0.048371
Hs.409412 NM_005484 PARP2 Poly (ADP-ribose) polymerase 2 1.0899 0.160191
Hs.171844 NM_006505 PVR Poliovirus receptor −1.0185 0.2427
Hs.463642 NM_003161 RPS6KB1 Ribosomal protein S6 kinase, 70 kDa, polypeptide 1 1.1352 0.310545
Hs.21374 NM_000345 SNCA Synuclein, alpha (non A4 component of amyloid precursor) −1.7882 0.009952
Hs.48513 NM_006038 SPATA2 Spermatogenesis associated 2 −1.3653 0.694708
Hs.587290 NM_003900 SQSTM1 Sequestosome 1 −1.073 0.076573
Hs.189782 NM_018202 TMEM57 Transmembrane protein 57 −1.0805 0.149693
Hs.241570 NM_000594 TNF Tumor necrosis factor −1.7491 0.009952
Hs.591834 NM_003844 TNFRSF10A Tumor necrosis factor receptor superfamily, member 10a 1.2277 0.200162
Hs.713833 NM_001065 TNFRSF1A Tumor necrosis factor receptor superfamily, member 1A −1.4144 0.047858
Hs.437460 NM_000546 TP53 Tumor protein p53 −1.1421 0.259099
Hs.522506 NM_021138 TRAF2 TNF receptor-associated factor 2 −1.4742 0.036574
Hs.134406 NM_017853 TXNL4B Thioredoxin-like 4B −1.2299 0.083412
Hs.47061 NM_003565 ULK1 Unc-51-like kinase 1 (C. elegans) −1.7787 0.146981
Table 1. Transcriptional modulation of a subset of genes involved in human death cell signalling pathways 
in 4-HBA treated A549 cells. Gene transcription is considered unaffected by compound treatment if fold 
regulation is in the range ± 2.0.
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selected and subjected to treatment with all HBA chemical isomers (Figure S6). Again only 4-HBA was able to 
inhibit HT29 cell proliferation.
Data reported here disclose the role of 4-HBA as a novel inducer of pyroptosis. We forecast that 4-HBA will 
become a useful tool for elucidating still unknown molecular relationships between pyroptosis and cancer.
Methods
Bacterial strains and culture conditions. Each Antarctic bacteria strain (see Table S1) were grown aer-
obically in flasks at 15 °C in GG defined medium16 (10 g L−1 L-Glutamate, 10 g L−1 D-Gluconate, 1 g L−1 K2HPO4, 
10 g L−1 NaCl, 1 g L−1 NH4NO3, 200 mg L−1 MgSO4∙7H2O, 5 mg L−1 FeSO4∙7H2O, 5 mg L−1 CaCl2∙2H2O pH 7.5) or 
TYP medium17 (16 g L−1 yeast extract, 16 g L−1 bacto Tryptone, 10 g L−1 NaCl). At the end of the exponential phase 
cells and spent medium were harvested.
Bacterial fermentation. Pseudoalteromonas haloplanktis TAC125 growth was performed in a Stirrer Tank 
Reactor 7L Bioreactor Techfors S (INFORS HT) connected to an IRIS 5.0 software with a working volume of 
7L. Fermentation was performed in 5L of GG defined medium. The bioreactor was equipped with the standard 
pH, pO2, and temperature sensor for bioprocess monitoring. The culture was carried out at 15 °C for 31 hours in 
aerobic conditions DOT (dissolved oxygen tension) ≥20%, using an airflow of 1.5 L/hour, and a stirrer speed of 
250 rpm.
Total bacterial extracts preparation. Cold-adapted bacterial cultures (cells and spent medium), pre-
viously frozen at −80 °C, without adding cryoprotectants, were thawed and stirred with an equal volume of 
ethyl acetate (Assay Percent Range ≥99.5%) (Sigma-Aldrich) and mixed with 1% formic acid (Assay Percent 
Range = 90%) (JT Baker). Each solution was stirred at least for 30 min and then centrifuged at 3000 rpm for 
30 min. The resulting two phases were separated and the organic phases were recovered and dried using a rotary 
evaporator, Rotavapor (Buchi R-210) at 40 °C. The resulting total organic extracts were dispensed and stored at 
−20 °C.
Anticancer compound purification and identification. Sample purification. The crude extract was 
pre-fractionated on a reversed phase C18 flash column (10 g, 15 ml) using an Isolera One automated flash system 
(BIOTAGE, Uppsala, Sweden). The gradient was 10% stepwise (15 column volumes) from 30–100% methanol 
Figure 3. Histograms showing the effects of 4-HBA (1 µg ml−1, IC50 concentration) on target genes expression 
and proteins levels in A549 lung adenocarcinoma cells. Panel (A): Gene expression analysis after 2 hours of 
treatment with the compound; three independent assays were performed in triplicate and the data are expressed 
as mean ± S.D. Expression values greater or lower than a two-fold difference with respect to the controls were 
considered significant (black bar). Panels (B, C and D): Histograms show the effects after 24 hours of 4-HBA 
treatment (1 µg ml−1, IC50 concentration) on expression levels of target proteins in A549 lung adenocarcinoma 
cells. (B) Pro_Caspase1; (C) Caspase1_p20 cleavage fragment; (D) control protein, β-Actin. Three independent 
assays were performed in triplicate; data are shown as mean ± S.D.
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(MeOH) buffered with 20 mM formic acid with a flow of 15 ml/min. Nine fractions were collected manually every 
10% step. MeOH was of HPLC grade and water was purified and deionized using a Millipore system through a 
0.22 μM membrane filter (Milli-Q water).
4-Hydroxybenzoic acid (fraction 1E) was purified from the Isolera fraction (fraction 1) on a Waters 
semi-preparative HPLC, with a Waters 600 Controller (Milford, MA, USA) coupled to a Waters 996 Photodiode 
Array Detector. Separation was achieved on a Luna II C18, 5 μm, 250 × 10 mm column (Phenomenex, Torrance, 
CA, USA) with a flow of 5 ml min−1 using a linear gradient 5% MeCN in Milli-Q water with 50 ppm TFA going 
to 35% MeCN in 24 min, from 35–45% MeCN in 2 min, 45–100% MeCN in 2 min, kept for 5 min at 100% MeCN 
and down to the starting conditions in 2 min. MeCN was of HPLC grade.
4-HBA identification. The identification of 4-HBA was performed using ultra-high performance liquid 
chromatography-diode array detection-quadrupole time of flight mass spectrometry (UHPLC-DAD-QTOFMS) 
with tandem HRMS fragmentation on an Agilent Infinity 1290 UHPLC system (Agilent Technologies, Santa 
Clara, CA, USA) equipped with a DAD and an Agilent 6550 iFunnel QTOF MS (as previously described18) and 
comparing results obtained with spectra acquired using the commercial standards.
Commercial standards. 4-hydroxybenzoic acid, 3-hydroxybenzoic acid and 2-hydroxybenzoic acid (salicylic 
acid) were purchased at Sigma-Aldrich (Steinheim, Germany).
Treatment of Human Cells. The adenocarcinoma human alveolar basal epithelial cell line A549 was purchased 
from the American Type Culture Collection (ATCC® CCL185™) and grown in DMEM-F12 (Dulbecco’s mod-
ified Eagle’s medium) supplemented with 10% (v/v) of fetal bovine serum (FBS), 100 units ml−1 penicillin and 
100 µg ml−1 streptomycin. The normal diploid human lung fibroblasts WI-38 were purchased from the American 
Type Culture Collection (ATCC® CCL-75™) and grown in MEM supplemented with 10% (v/v) of fetal bovine 
serum (FBS), 100 units ml−1 penicillin and 100 µg ml−1 streptomycin, 2 mM of L-glutamine and non-essential 
amino acids (NEAA, 2 mM). The human colorectal adenocarcinoma cell line HT29 was purchased from the 
American Type Culture Collection (ATCC® HTB38) and maintained in McCoy’s 5 A medium supplemented 
with 10% (v/v) fetal bovine serum (FBS), 2 mmole L−1 glutamine and 100 units ml−1 penicillin and 100 µg ml−1 
streptomycin. The medium was renewed every 3 days, and the cells were detached via trypsinization when they 
reached confluence. Before the experiments, cells were seeded in 96-well plates (2 × 103 cells well−1) and kept 
overnight for attachment. For viability assays, the extracts, fractions and pure compound(s) were dissolved in 
dimethyl sulfoxide at a final concentration of 1% (v/v) for each treatment.
MTT- Viability assay. The effect of extracts, fractions and pure compound(s) on cell viability were determined 
using the 3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide (MTT) assay (Applichem A2231). 
A549, HT29 and WI-38 cells, seeded in 96-well plates, after treatment times (24 and 48 hours), were treated 
with 10 µl (5 mg ml−1) of MTT and incubated for 3 hours. After the incubation time, isopropanol was used to 
dissolve purple formazan crystals. The absorbance was recorded on a microplate reader at a wavelength of 570 nm 
(Multiskan FC, THERMO SCIENTIFIC). The effect on cell viability was evaluated as percent of cell viability cal-
culated as the ratio between mean absorbance of each sample and mean absorbance of controls.
RT2 profiler PCR-array analysis for cell death pathway identification. A549 (2 × 106) cells used 
for RNA extraction and analysis, were seeded in Petri dishes (100 mm diameter) to obtain the control condition 
without any treatment and cells treated with the IC50 concentration of the pure compound (1 µg ml−1). After 
2 hours of exposure time, A549 cells were washed directly in the Petri dish by adding cold Phosphate-Buffered 
Saline (PBS) and rocking gently.
Cells were lysed in the Petri dish by adding 1 ml of Trisure Reagent (Bioline, cat. BIO-38033) per 100 mm dish 
diameter. RNA was isolated according to the manufacturer’s protocol. RNA concentration and purity was assessed 
using the nanophotomer NanodroP (Euroclone).
About 200 ng RNA was subjected to reverse transcription reaction using the RT2 first strand kit (Qiagen, cat. 
330401) according to the manufacturer’s instructions. The qRT-PCR analysis was performed in triplicate using 
the RT2 Profiler PCR Array kit (Qiagen, cat. 330231), in order to analyze the expression of death cell signaling 
genes on A549 cells. Plates were run on a ViiA7 (Applied Biosystems 384 well blocks), Standard Fast PCR Cycling 
protocol with 10 µl reaction volumes. Cycling conditions used were: 1 cycle initiation at 95.0 °C for 10 min fol-
lowed by amplification for 40 cycles at 95.0 °C for 15 s and 60.0 °C for 1 min. Amplification data were collected via 
ViiA 7 RUO Software (Applied Biosystems). The cycle threshold (Ct)-values were analyzed with PCR array data 
analysis online software (http://pcrdataanalysis.sabiosciences.com/pcr/arrayanalysis.php, Qiagen). Control genes 
for Real-Time qPCR were actin-beta (ACTB), beta-2-microglobulin (B2M), hypoxanthine phosphoribosyltrans-
ferase (HPRT1) and ribosomal protein, large subunit P0 (RPLP0), the expression of which remained constant in 
A549 cells.
Protein extraction and immunoblot analysis. A549 cells (2 × 106), were seeded in Petri dishes (100 mm 
diameter) and cultured without any treatments (untreated control) or with the IC50 concentration of the pure 
compound (4-HBA, 1 µg ml−1). A549 cell lysates were prepared after 24 hours of treatment by scraping the cells 
of each Petri dish into 1 ml of Radio Immune Precipitation Assay buffer (RIPA, Cell Signaling, cat. 9806), sup-
plemented with 1 µM of protease inhibitor PMSF (Cell Signaling, cat. 8553). The lysates were incubated on ice 
for 15 min and then clarified by centrifugation at 14000 × g, for 20 min. Total protein concentrations were deter-
mined according to the Bradford method using the Protein Assay Reagent (Applichem, cat. A6932) with bovine 
serum albumin (BSA, Sigma Aldrich, cat. A2058) as standard. The protein extracts were stored at −20 °C until 
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use. Before electrophoresis, protein samples were incubated at 100 °C for 5 min. Following 10% SDS-PAGE, gels 
were stained with Comassie or blotted onto nitrocellulose membrane (Biorad, cat. 170–4159). Membranes were 
incubated for 1 hour in blocking reagent (1 × Tris Buffered Saline-TBS), with 0.1% Tween-20 with 5% w/v nonfat 
dry milk, and incubated overnight at 4 °C with the primary antibodies diluted in 1 × TBS, 0.1% Tween-20 with 
5% BSA (CASP1, 1:1000, Biorbyt orb10232).
After incubation, membranes were washed three times for 10 min each with 15 ml of TBS/Tween and then 
incubated with HRP-conjugated secondary antibody with gentle agitation for 1 h at room temperature. For 
β-actin, we used HRP-conjugated secondary antibody anti-mouse (1:10000, Santa Cruz Biotechnology); for 
CASP1 we used HRP-conjugated secondary antibody anti-rabbit (1:10000, Jackson ImmunoResearch).
After incubation, membranes were washed three times for 10 min each with 15 ml of TBS/Tween. Blotted 
membranes were immunodetected using clarity Western ECL (Biorad, cat. 170-5060). Proteins were visualized 
with Fuji medical X-ray film (cat. 47410). Densitometric analysis of immunopositive bands was performed using 
ImageJ software.
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